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Abstract
Background
Lung cancer is a good example of the potential benefit of symptom-based diagnosis, as it is
the commonest cancer worldwide, with the highest mortality from late diagnosis and poor
symptom recognition. The diagnosis and risk assessment tools currently available have
been shown to require further validation. In this study, we determine the symptoms associ-
ated with lung cancer prior to diagnosis and demonstrate that by separating prior risk based
on factors such as smoking history and age, from presenting symptoms and combining
them at the individual patient level, we can make greater use of this knowledge to create a
practical framework for the symptomatic diagnosis of individual patients presenting in pri-
mary care.
Aim
To provide an evidence-based analysis of symptoms observed in lung cancer patients prior
to diagnosis.
Design and setting
Systematic review and meta-analysis of primary and secondary care data.
Method
Seven databases were searched (MEDLINE, Embase, Cumulative Index to Nursing and
Allied Health Literature, Health Management Information Consortium, Web of Science, Brit-
ish Nursing Index and Cochrane Library). Thirteen studies were selected based on predeter-
mined eligibility and quality criteria for diagnostic assessment to establish the value of
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symptom-based diagnosis using diagnosistic odds ratio (DOR) and summary receiver oper-
ating characteristic (SROC) curve. In addition, routinely collated real-time data from primary
care electronic health records (EHR), TransHis, was analysed to compare with our findings.
Results
Haemoptysis was found to have the greatest diagnostic value for lung cancer, diagnostic
odds ratio (DOR) 6.39 (3.32–12.28), followed by dyspnoea 2.73 (1.54–4.85) then cough
2.64 (1.24–5.64) and lastly chest pain 2.02 (0.88–4.60). The use of symptom-based diagno-
sis to accurately diagnose lung cancer cases from non-cases was determined using the
summary receiver operating characteristic (SROC) curve, the area under the curve (AUC)
was consistently above 0.6 for each of the symptoms described, indicating reasonable dis-
criminatory power. The positive predictive value (PPV) of diagnostic symptoms depends on
an individual’s prior risk of lung cancer, as well as their presenting symptom pattern. For at
risk individuals we calculated prior risk using validated epidemiological models for risk fac-
tors such as age and smoking history, then combined with the calculated likelihood ratios for
each symptom to establish posterior risk or positive predictive value (PPV).
Conclusion
Our findings show that there is diagnostic value in the clinical symptoms associated with
lung cancer and the potential benefit of characterising these symptoms using routine data
studies to identify high-risk patients.
Introduction
Lung cancer has the highest mortality rate of any cancer worldwide and constitutes more than
40% of all new cancer diagnoses [1]. Although survival rates in England have improved in the last
40 years, they remain lower than in comparable European countries. Improving early diagnosis is
a key component of relieving the cancer burden [2]. It has been estimated that earlier diagnosis of
the four commonest cancers in England (lung, breast, prostate and colorectal), would benefit over
11,000 patients each year [3]. The National Institute for Health and Care Excellence (NICE) 2015
urgent referral guidelines for suspected cancer, set the positive predictive value (PPV) threshold of
clinical presentations for cancer at 3% [4]. In this study, we aim to determine the validity of symp-
tom-based lung cancer diagnosis, using published studies, routine data from electronic health rec-
ords and published prior risk models. A recent review of lung cancer diagnosis using ‘Risk
Assessment Tools’ (RATs) found that there was insufficient validation, and that the inclusion of
‘epidemiological risk factors’ in the models, along with symptoms, created confounders [5]. In
this review, we specifically assess symptoms associated with lung cancer diagnosis without epide-
miological factors, to avoid confounding. We can then determine the prior risk using epidemio-
logical models and calculate the posterior probability, or PPV, using Bayes’ theorem.
Methods
Systematic literature search
We performed a systematic review and meta-analysis of studies reporting the sensitivity, speci-
ficity, predictive values, odds ratios or likelihood ratios for lung cancer in patients consulting
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their GP with symptoms prior to diagnosis. Searches were performed on 24th September 2017
of seven databases using search terms specific for lung cancer diagnosis (Fig 1) presented
using the prisma flow chart [6]. For prisma checklist and full search terms and outcomes, see
S1 and S3 Tables.
Fig 1. Prisma flow chart of database search.
https://doi.org/10.1371/journal.pone.0207686.g001
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Eligibility criteria
Eligible studies were performed in either a primary or secondary care setting. They included
male and/or female subjects, 15 years and over, with appropriate demographic information.
All cases were diagnosed with primary lung cancer using imaging and/or histological data,
assessed by a trained clinician. The presentation of symptoms prior to a diagnosis of primary
lung cancer had to be clearly described in each of the selected studies and recorded prior to
diagnosis. Studies that did not include sufficient data for outcome analysis using a 2x2 conti-
gency table were excluded from the meta-analysis.
Data collection from the TransHis primary care electronic health record
The Transition Project “TransHis” is an electronic patient record used by 230 general practices
worldwide to collate data in real-time [7]. All patients whose initial consultations were subse-
quently linked to a diagnosis of lung cancer were assessed [8]. These allowed us to monitor the
evolution of an initial presenting symptom to its final diagnosis [9]. Data extraction was per-
formed on 24th September 2017.
Outcome analysis and statistical methods
For diagnostic analysis, we constructed 2x2 contingency tables for each study, using data col-
lated prior to diagnosis [10]. For the meta-analysis, a random effects model for diagnostic
accuracy was used to pool the data, as this accounts for differences in index test threshold,
based on patient and/or clinical interpretation of presentations. A measure of the discrimina-
tory power of the index test was calculated using diagnostic odds ratios (DOR). Heterogeneity
in results across a study was assessed for each presenting symptom as a subgroup using
Cochran’s Q (Q�) and I-squared (I2) statistics [11, 12]. Summary Receiver Operating Charac-
teristic (SROC) curves for each presenting symptom were plotted from pooled sensitivity
against (1-pooled specificity) using Moses’ Model (weighted regression, inverse variance). The
area under the curve (AUC) was used to measure diagnostic accuracy. STATA version 13
(STATACorp, USA) was used for the statistical analyses.
Results
The search strategy shown in Fig 1, produced 13,430 unique references. A further review of
these titles followed by abstracts and selection of those studies that met the inclusion criteria,
resulted in the selection of 34 studies by the first reviewer (GO). A full text review of the 34
studies was performed by the first and second reviewer independently (GO and BD) with
good agreement, kappa of 0.85 (0.430–0.938). After discussion, a final thirteen studies were
selected. All findings were reported in accordance with PRISMA guidelines.
Study strengths, limitations and bias assessment
The design and protocol used in each of the selected studies were subject to different types of
bias (Table 1). The selected studies include six case series, three case-control and four cohort
studies, summarised in Tables 2 and 3. Likelihood ratios (LR) are the most clinically useful
outcome measures, as the LR is the probability of a cancer patient having the symptom divided
by the probability of a non-cancer patient having that symptom. Table 3 details those studies
where likelihood ratios could be calculated. Five of the selected studies included sufficient data
to assess the diagnostic accuracy of symptoms associated with lung cancer using a dichoto-
mous test approach. This data was compared with LRs from TransHis data.
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Cohort studies. Retrospective cohort studies typically use data collected in the electronic
health record: they usually exclude data collected in the 6–12 months before diagnosis to
address the potential bias from including post-diagnosis symptoms and to minimise the influ-
ence of GPs preferentially coding possible lung cancer symptoms when considering this as a
potential diagnosis. Cohort studies accounted for 31% of the selected studies. Jones and col-
leagues (2007), used a symptom-based approach to investigate all diagnoses associated with
haemoptysis in a large general practice database (Clinical Practice Research Datalink) of
762,325 UK patients. Of the 4,812 new episodes of haemoptysis, 6.3% were subsequently diag-
nosed with lung cancer. This study also reported PPVs and positive likelihood ratios (LR+) as
shown in Table 3 [13]. Hippisley-Cox and colleagues (2011) determined the hazard ratios for
lung cancer in a risk assessment model that considered three clinical predictors (haemoptysis,
loss of appetite and weight loss) presenting within 12 months prior to a lung cancer diagnosis.
Risk of lung cancer was greatest in patients with haemoptysis: hazard ratio 23.9 (20.6–27.6) in
females and 21.5 (19.3–23.9) in males, after adjustment for late-stage diagnosis and the associ-
ated shorter time-to-diagnosis, waiting time paradox [14]. Walter and colleagues (2015) used a
prospective cohort study design and interviewed patients who had been referred to a specialist
respiratory clinic by their GP. Half of the referred patients (49.3%) reported that they had pre-
sented to their GP with a single first symptom. Almost 40% (>37.8%) presented with more
than one presenting symptom that worsened over time. Haemoptysis had the greatest causa-
tive association to lung cancer with an adjusted hazard ratio of 2.17 (1.63–2.89) (P = 0.00) [15].
Table 1. Bias risk in selected studies.
Type of bias Case series studies Case-control studies Cohort studies
Koyi
et al.
2002
Corner
et al.
2005
Barros
et al.
2006
Cajoto
et al.
2009
Shresthra
et al. 2010
Gonzalez-
Baracala
et al. 2014
Kubik
et al.
2002
Hamilton
et al. 2005
Iyen-
Omofoman
et al. 2013
Hoppe
et al.
1977
Jones
et al.
2007
Hippisley-
Cox et al.
2011
Walter
et al.
2015
Random
sequence
generation
(selection bias)
� � � � � � � � � � � � �
Allocation
concealment
(selection bias)
� � � � � � � � � � � � �
Blinding of
participants and
personnel
(performance
bias)
� � � � � � � � � � � � �
Blinding
outcome
assessment
(detection bias)
� � � � � � � � � � � � �
Incomplete
outcome data
(attrition bias)
� � � � � � � � � � � � �
Selective
reporting
(attrition bias)
� � � � � � � � � � � � �
Other bias � � � � � � � � � � � � �
� Indicates high risk of bias
� Indicates uncertain risk of bias
� Indicates low risk of bias
https://doi.org/10.1371/journal.pone.0207686.t001
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Table 2. Summary of selected studies.
Study (year) Geographic
area
Study design Data source
period
Sample
demography and
use of controls
Period of
initial
presentation
Characterisation of
symptom
Staging or
surgical
management
Outcome
measure
Koyi et al.
2002
Gaevleborg,
Sweden
Prospective case
series study using
patient questio
-nnaires
completed within
a specialist lung
clinic
Patient
questionnaire
Jan 1997 –Dec
1999
364 participants–
no controls
Not stated Not characterised Yes Percentages
Corner et al.
2005
England,
United
Kingdom
Retrospective case
series study
interview
triangulated with
medical records
Medical Records
(< 2 years before
diagnosis)
22 participants
(Male 54.5%
Female 45.5%)–no
controls
6–24 months
prior to
diagnosis
Not characterised Yes,
operability
Percentages
Barros et al.
2006
Curitian,
Brazil
Retrospective case
series study
Medical records
Jan 1991- Dec
1997
268 participants–
no controls
Not stated Not characterised Yes Percentages
Cajoto et al.
2009
(SPANISH)
Santiago de
composteka,
Spain
Retrospective case
series study
Medical records
(codes)
Jan 1997-Dec
1999
481 participants–
no controls
Not stated Not characterised None Percentages
Shrethra et al.
2010
Kathmandu
Nepal
Retrospective case
series study
Medical records
July 2004—July
2008
174 participants–
no controls
117.3 days
prior to
diagnosis
Not characterised None Percentages
Gonzalez-
Barcala et al.
2014
Ponteveda
Health Area,
Spain
Retrospective case
series study
Hospital records
1 June 2005–31
May 2008
358 patients–no
controls
Unknown Not characterised Yes Percentages
Kubik et al.
2002
Czech
Republic
Case-control study Patient interview
questionnaire
(not validated)
April 1998—
October
2000
All female 268
cases and 1076
control
participants (not
diagnosed with
lung cancer), aged
25–89.
< 2 years Yes, duration of
presentation- looked
at two presentations.
Also, one associated
feature, cough +/-
phlegm.
None Odds Ratio
(adjusted for
age, residence
and
education)
Hamilton
et al. 2005
Exeter,
United
Kingdom
Case-control study
controls
GP Medical
records (codes)
1998–2002
247 cases and 1235
control
participants no
lung cancer with
same presentation
(GP/age/sex
matched, age >40
years)
180 days to 2
years
Yes, associated
symptoms as first and
second symptom prior
to diagnosis for seven
specific symptoms.
None Positive
Predictive
Value and
Likelihood
Ratios
Iyen-
Omoforman
et al. 2013
United
Kingdom
Case-control
study–controls
from same general
practice
GP Medical
records (The
Health
Improvement
Network
database)
Jan 2000—July
2009
12, 074 cases and
120,731 control
participants
4–12 months
13–24
months
Yes, onset (period
prior to diagnose) five
specific symptoms
None Odds Ratio,
sensitivity,
specificity
Hoppe et al.
1977
(GERMAN)
Hamburg,
Germany
Retrospective
Cohort study
Hospital records
1967–1974
20,000 participants
in cohort
Not stated Yes, duration of
symptom prior to
diagnosis
None Percentages
Jones et al.
2007
United
Kingdom
Retrospective
Cohort study
Medical records
(CPRD)
Jan 1994—Dec
2000
4812 participants
(>15 years) in
cohort
6 months– 3
years
Assessed haemoptysis
only as a lung cancer
symptom.
None Positive
Predictive
Value,
Likelihood
Ratios
(Continued)
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Case-control studies. Case-control studies accounted for 23% of the selected studies and
are limited in that the outcome measures such as PPVs cannot be generalised beyond the
study. They are a product of the selection of cases and controls, not reflecting any natural
Table 2. (Continued)
Study (year) Geographic
area
Study design Data source
period
Sample
demography and
use of controls
Period of
initial
presentation
Characterisation of
symptom
Staging or
surgical
management
Outcome
measure
Hippisley-cox
et al. 2011
England and
Wales,
United
Kingdom
Prospective
Cohort study
GP Medical
records
(QResearch
EMIS)
Jan 2000- Sept
2010
3785 participants
in cohort
< 2 years Not characterised None Positive
predictive
value
Walter et al.
2015
England
United
Kingdom
Prospective
Cohort study
Medical records
and
Questionnaire
completed by
interviewer
Dec 2010 and
Dec 2012
963 participants in
cohort
28 days– 2
years
Yes, duration and
presence of
synchronous
symptoms
None Hazard ratios
(adjusted for
waiting time)
and
percentages
https://doi.org/10.1371/journal.pone.0207686.t002
Table 3. Likelihood ratios for each presentation where indicted in selected studies.
Study (year) Outcome measure Symptom
Hamilton et al.
2005
LR+
(from raw data obtained from a
referenced author)
Haemoptysis LR+13.2 (7.9–22) LR- 0.8 (0.76–0.86); Loss of
weight LR+ 6.2 (4.5–8.6) LR- 0.76 (0.71–0.82); Loss of
appetite LR+4.8 (3.3–7.0) LR- 0.84 (0.79–0.9); Dyspnoea LR
+3.6 (3.1–4.3) LR- 0.52 (0.45–0.60); Chest or rib pain LR
+3.3 (2.7–4.1) LR- 0.68 (0.61–0.75); Fatigue LR+2.3 (1.
9–2.9) LR-0.76 (0.7–0.84).
Iyen-Omoforman
et al. 2013
LR+ calculated from published
sensitivity and specificity
Haemoptysis 13.9; Cough 2.5; Chest/shoulder pain 1.9;
Dyspnoea 5.4; Weight loss 3.6; Voice hoarseness 1.9.
Jones et al. 2007 LR+ and PPV PPV 5.8% (5.0%-6.7%) and LR+ 116.7 (99.1–134.3) in men,
and PPV 3.3% (2.6%-4.3%) and LR+ 153.1 (115.3–190.8) in
women
Study (year) Outcome measure where LR
not available
Symptom
Kubik et al. 2000 OR
(adjusted for age, residence,
education and pack years)
Chronic cough 2.93 (2.03–4.22); Chronic phlegm 2.44
(1.59–3.76); Chronic phlegm < 2 years 4.74 (2.56–8.76);
Chronic phlegm�2 years 1.43 (0.80–2.54); Dyspnoea 1.66
(1.18–2.34); Attacks of dyspnoea 1.10 (0.60–2.04).
Hippisley-cox et al.
2011
PPV Current haemoptysis female 23.9 (20.6–27.6) male 21.5
(19.3–23.9); Current appetite loss female 4.14 (3.15–5.45)
male 4.71 (3.69–6.00); Current weight loss female 4.52
(3.80–5.38) male 6.09 (5.33–6.95); New onset cough in last
12 months female 1.90 (1.56–2.32) male 1.47 (1.23–1.75)
Walter et al. 2015 HR
(adjusted for waiting time
paradox)
Coughing up blood (not included as less than 10 cases);
Cough or worsening cough 43 weeks 1.16 (0.78–1.74)
P = 0.46; Breathlessness or worsening 43 weeks 0.70 (0.45–
1.08) P = 0.1; Chest/shoulder pain 43 weeks 1.79 (1.08–2.99)
P = 0.03; Hoarseness 43 weeks 0.98 (0.48–2.01) P = 0.97;
Decreased appetite 1.41 (0.78–2.53) P = 0.25; Unexplained
weight loss 0.86 (0.43–1.71) P = 0.66; Fatigue or tiredness
‘unusual for you’ 1.16 (0.75–1.79) P = 0.49; Different ‘in
yourself’ 1.52 (0.93–2.46) P = 0.09.
LR+ = positive likelihood ratio, PPV = positive predictive value, OR = odds ratio, HR = hazard ratio
https://doi.org/10.1371/journal.pone.0207686.t003
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population, although LRs may be valid for use with prior risk data. Kubik and colleagues
(2000) assessed the diagnostic value of dyspnoea, chronic non-productive and productive
cough. When adjusted for age, residence, education, and smoking pack-years, non-productive
cough had an odds ratio of 2.93 (2.03–4.22), higher than that for productive cough 2.44 (1.59–
3.76) and dyspnoea 1.66 (1.18–2.34) [16]. Hamilton and colleagues (2005) used a case-control
study design to investigate the clinical features of lung cancer before diagnosis. Cases were
identified retrospectively from local general practices and cancer registry databases. Symptoms
reported within 180 days to 2 years prior to lung cancer diagnosis were assessed, to avoid bias,
and compared with age and sex-matched control groups from the same general practices who
did not have lung cancer. Seven specific presentations were assessed with the greatest positive
likelihood ratios observed with haemoptysis 13.2 (7.9–22.0), then loss of weight 6.2 (4.5–8.6),
loss of appetite 4.8 (3.3–7.0), dyspnoea 3.6 (3.1–4.3) and chest pain 3.3 (2.7–4.1)[17]. Iyen-
Omofoman and colleagues (2013) used a routine data source (The Health Improvement Net-
work). Clinical predictors were recorded during two time periods: 4–12 and 13–24 months
prior to diagnosis. The highest odds ratio: 20.15 (16.24–25.01) was for haemoptysis presenting
4–12 months before diagnosis[18].
Case series studies. Case series studies accounted for 46% of the selected studies, the most
common study design observed in this review but the least informative in relation to diagnos-
tic value. The diagnostic value of these symptoms cannot be assessed because patients without
lung cancer were not included in the study.
TransHis data. TransHis is an EHR specifically designed to capture the initial consulta-
tion as ‘Reason for Encounter’ (RfE) and maintain the episode of care structure as an ongoing
prospective cohort study. The TransHis data were used to determine the relationship between
lung cancer diagnosis and RfE, expressed as odds ratios. Cough followed by haemoptysis, dys-
pnoea, weight loss, chest pain and voice symptoms were the most prevalent RfEs in patients
subsequently diagnosed with lung cancer (S5 Table). Constitutional symptoms (tiredness,
weight loss, anorexia, fever and sweating) were collectively the third most common. As Trans-
His data is captured from routine care using a primary-care specific classification (ICPC2) and
the odds ratios are relative to ‘all consulting patients’, we compared the outcomes with our
selected studies.
When considering all the selected studies, haemoptysis, cough, dyspnoea, chest pain and
constitutional symptoms were found to be the most prevalent presentations. In all studies hae-
moptysis, dyspnoea and cough were consistently the most predictive symptom for lung cancer.
Statistical analysis for diagnostic accuracy of clinical presentations associated with lung
cancer. Five studies enabled us to assess the diagnostic accuracy of symptoms associated with
lung cancer [16–18]. The pooled diagnostic odds ratios (DOR) for.haemoptysis, dyspnoea,
cough and chest pain were 6.39 (3.32–12.28), 2.73 (1.54–4.85), cough 2.64 (1.24–5.64) and
chest pain 2.01 (0.88–4.6) respectively, shown in Figs 2–5 respectively.
Fig 2. Forest plots with pooled diagnostic odds ratio (95% confidence interval) and weights calculated using a
random effects model for haemoptysis in the diagnosis of lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g002
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Summary Receiver Operating Characteristic (SROC) curves were used to determine the
predictive accuracy of each presentation in the diagnosis of lung cancer, using the area under
the curve (AUC). Accuracy for lung cancer diagnosis was confirmed for haemoptysis
AUC = 0.65, dyspnoea AUC = 0.65, cough AUC = 0.68 and chest pain AUC = 0.79. The SROC
curves are summarised Figs 6–9 respectively.
The limited availability of studies that fit the criteria for diagnostic value, differences in
study design and the differing thresholds for recording presence/absence of a symptom,
shown in Tables 2 and 3, created the heterogeneity (I2) observed in the SROC curves Fig 3. We
compared the overall diagnostic value of each presentation from the selected studies with mea-
surable outcome data and TransHis data using likelihood ratios as shown in Table 4.
The symptom most likely to be observed in lung cancer vs non lung cancer patients is hae-
moptysis, followed by dyspnoea, cough and finally chest pain.
Staging at diagnosis of lung cancer. The tumour stage at diagnosis, or its operability, was
indicated in only four of the thirteen studies and most of the diagnosed cases were inoperable
or at stages IIa and above. Hence, 31% of selected studies described the prognostic benefits of
symptom-based early diagnosis by including data on disease stage and operability at diagnosis
[14, 15, 17–19].
In the most common form of lung cancer, non-small cell, the weighted means as a percent-
age of all cases in each study was calculated as follows: Stage I 10.7%, Stage II 6.9%, Stage III
43.2% and Stage IV 39.2%. These studies found that less than 8.2% of the lung cancer patients
were amenable to surgery at diagnosis [20].
Discussion
Summary of findings
We found haemoptysis, had the greatest diagnostic value in both the selected studies and the
TransHis database, followed by dyspnoea, cough and chest pain. The review also indicated
Fig 3. Forest plots with pooled diagnostic odds ratio (95% confidence interval) and weights calculated using a
random effects model for Dyspnoea in the diagnosis of lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g003
Fig 4. Forest plots with pooled diagnostic odds ratio (95% confidence interval) and weights calculated using a
random effects model for Cough in the diagnosis of lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g004
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that most of cancer patients are diagnosed at a late stage when there are limited surgical man-
agement options and less favourable clinical outcomes. More precise coding for symptoms
and characterisation of symptoms, such as severity, timing and associated features, in elec-
tronic health records such as TransHis may provide sufficient evidence for early symptom-
based diagnosis of lung cancer. It is hoped that the introduction of a new and global clinical
vocabulary for electronic health records, SNOMED CT (Systematized Nomenclature of Medi-
cine–Clinical Terms), will also contribute to better utilisation of electronic health records to
improve evidence-based research. Although, codes will need to be carefully restricted to a clas-
sification of symptoms to enable calculation of odds ratios.
Findings within the context of the current literature
To date, this is the only review to include a meta-analysis of clinical symptoms for the diagno-
sis of lung cancer. A previously published systematic review based on primary care data
Fig 5. Forest plots with pooled diagnostic odds ratio (95% confidence interval) and weights calculated using a
random effects model for Chest Pain in the diagnosis of lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g005
Fig 6. Summary Receiver Operator Curve for Haemoptysis as a diagnostic symptom in lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g006
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Fig 7. Summary Receiver Operator Curve for Dyspnoea as a diagnostic symptom in lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g007
Fig 8. Summary Receiver Operator Curve for Cough as a diagnostic symptom in lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g008
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showed haemoptysis to be a predictor of lung cancer, but there were insufficient data to per-
form a meta-analysis [21]. We included studies where the index cases were identified in both
primary care and secondary care studies as long as patients were referred by their GP. We
made this decision on the basis that referral to a clinic for investigation of respiratory symp-
toms represents a cohort of people in whom the GP is considering cancer, and in the absence
of better data on the evolution of symptoms over time, may yield useful LRs (but not PPVs).
Our findings are consistent with previous findings that haemoptysis is predictive of lung can-
cer, but in addition demonstrates the diagnostic value of dyspnoea, cough and chest pain [15,
18, 21, 22].
Previously published studies suggest that efforts to expedite the diagnosis of symptomatic
cancer are likely to benefit patients in terms of improved survival, earlier-stage diagnosis and
improved quality of life [19, 23–27]. This review clearly identifies a place for symptom-based
diagnosis, as the epidemiology of cancer symptoms is becoming better understood. Risk mod-
els that assess prior risk factors and then presenting symptoms could identify high-risk patients
for early diagnosis [28].
Table 4. Positive Likelihood Ratios (LR) for symptoms in Lung Cancer patients prior to diagnosis.
Symptom Pooled positive likelihood ratio for selected studies
(95% confidence intervals)
TransHis positive likelihood ratios (95%
confidence intervals)
Haemoptysis 5.968 (3.183–11.189) 51.76 (24.91–107.56)
Dyspnoea 2.138 (1.350–3.385) 3.02 (1.72–5.32)
Cough 1.748 (1.290–2.369) 1.09 (0.69–1.73)
Chest pain 1.756 (0.953–3.237) 0.69 (0.17–2.73)
https://doi.org/10.1371/journal.pone.0207686.t004
Fig 9. Summary Receiver Operator Curve for Chest pain as a diagnostic symptom in lung cancer.
https://doi.org/10.1371/journal.pone.0207686.g009
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Strengths and weaknesses of the review
All selected studies used routine data sources, a cost-effective and powerful resource for evi-
dence-based research. Though variability in the study designs creates heterogeneity, there was
sufficient data to perform a meta-analysis and determine the diagnostic accuracy of clinical
presentations associated with lung cancer. Five of the thirteen studies assessed the association
of lung cancer with a specific set of symptoms and did not investigate all symptoms reported
in lung cancer patients [13, 14, 16–18]. As a result, their findings may have missed other symp-
toms not already known to be associated with lung cancer. Each study provided demographic
data on age, sex and smoking status; male smokers over 40 years were found to have the great-
est incidence of lung cancer. However, routine data sources can also be subject to bias, such as
missing data, coding inconsistencies, and work-up bias [29, 30] Thus, these studies can miss
the complexities of the clinical assessment necessary for cancer diagnosis, for example weight
loss was found to be the fifth most prevalent presentation prior to diagnosis and, in one study,
it was observed even in operable disease, indicative of a presentation associated with early
diagnosis [31]. In 62% of the selected studies, weight loss was grouped with constitutional
symptoms, therefore, specific analysis of weight loss as an isolated symptom was not possible.
More data are required for diagnostic assessment of weight loss because it may prove to be a
cost-effective predictor of high-risk patients. These patients could be identified for further
investigations to facilitate early cancer diagnosis.
Implications for clinical practice and research
Case series studies represent a majority of the studies into symptoms associated with lung can-
cer, but this design has no diagnostic benefit because there are no controls. This highlights the
importance of devising a study design that will produce clinically significant outcomes that
will be of patient benefit.
Understanding the precise diagnostic value of symptoms is a powerful tool in clinical deci-
sion making [28]. Table 5 outlines three case scenarios where symptomology is considered in
combination with prior risk [32] to establish indivualised risk and appropriate management.
Up to 20% of all chest X-ray requests from primary care in patients subsequently diagnosed
with lung cancer are negative [33, 34]. If we consider a high posterior risk of lung cancer, as
shown in the Case C, even with a negative chest X-ray this patient still meets the criteria for
urgent referral (PPV>3%), based on epidemiological risk factors and symptomology using
Bayesian incorporation for posterior risk [17, 23, 35–39].
Over-reliance on chest X-ray findings and ignoring the patient’s prior risk could result in a
missed diagnosis. This observation is reflected in the most recent NICE guidelines for referral
of suspected cancer, it supports better primary care access to high-resolution imaging when
indicated for high-risk patients [4].
Hamilton et al., 2005 investigated first and subsequent presenting symptom in lung cancer
patients. Raw data from this study was utilised in the Bayesian model for risk of lung cancer
described Table 5. Walters et al., 2015 looked at synchronous symptoms that occurred at the
same time but did not define the specific symptom only the frequency of a single or synchro-
nous symptom at first presentation.
In this systematic review we provide supporting evidence for four important symptoms for
lung cancer diagnosis: haemoptysis, dyspnoea, cough and chest pain. It also highlights the dif-
ficulties with evaluating the diagnostic value of constitutional symptoms. For the diagnosis of
relatively rare conditions such as cancer, population-based prospective cohort studies may
never be feasible, hence, Walter and colleagues (2015) used selected high-risk patients. As we
reach the limit of what we can be achieve with routine data in their current form, we must
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develop more defined and sophisticated criteria for clinical coding of symptoms and routine
risk stratification of patients in real-time during clinical decision making [40, 41].
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Table 5. Clinical case analysis using prior risk assessment and Bayesian incorporation of clinical symptoms to determine posterior risk.
Case Sex Age Smoking
status
Age
started
Age
stopped
Smoking
duration
Smoking
intensity
(cigarettes/
day)
Symptoms LR+ Calculated
prior risk %
PPV
Calculated on the
basis of individual
posterior risk %
PPV based on
presenting
symptoms in the
published cohort[17]�
A M 68 Smoker 20 NA 48 10 cough +
fatigue
3.45 1.86 6.14%
Moderate risk
0.63%
Low risk
Case A represents a low risk patient based on symptoms alone and therefore would not require further investigation or referral. When we take into account prior risk
defined by age, sex, smoking status and intensity, this patient is at greater risk then the moderate risk patient in Case B below and does require further investigation
(chest X-ray).
B F 61 Never NA NA NA NA dyspnoea
+ haemoptysis
27.98 0.124 3.36%
Moderate risk
4.90%
Moderate risk
Case B represents a patient with moderate risk when considering symptoms alone. Here consideration of prior risk has little effect on the risk status.
C M 58 Ex 17 47 30 10 loss of
appetite
+ haemoptysis
449.74 0.2697 54.88%
High risk
45.28%
High risk
Case C represents a high risk patient based on symptoms and even with a negative chest X-ray this patient would require further investigation to exclude lung cancer
[17], as 20% of all chest X-ray requests from primary care in confirmed lung cancer patients are negative[33, 34]. The current cut-off of urgent cancer referrals in the
UK is PPV>3% so this patient would be considered at high risk and should be investigated further, regardless of the chest X-ray findings.
� from raw data provided by one of the referenced authors
Likelihood ratio = LR+ Positive predictive value = PPV
https://doi.org/10.1371/journal.pone.0207686.t005
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